Our Research Areas
As one of the top programs for cell-based therapies, our research focuses on improving transplantation outcomes by reducing or avoiding infection or relapses and investigating viral-specific cells.
The largest and most comprehensive bone tumor research program in the United States.
Physicians on the pediatric neuro-oncology research program work closely together to improve the cure rates for children with brain tumors by using the latest treatments available.
As one of the best pediatric cancer centers in the nation, experts in the care of childhood cancer are on the forefront of cutting-edge research and clinical trials.
The cancer genetics and genomics research laboratories occupy over 5,500 square feet of state-of-the-art laboratory space. The recently renovated areas are well equipped for research in genetics, genomics, and cellular and molecular biology.
Rapidly translating novel cell and gene therapy protocols from the laboratory to the clinic.
Nationally recognized as a major center for the development of novel chemotherapy approaches to pediatric cancer treatment.
Studying the causes of childhood cancer and hematological diseases to determine what can be done to prevent these conditions.
The Faris D. Virani Ewing Sarcoma Center has a strong emphasis on research. Our team has several targeted research goals, including developing a greater understanding of the:
As one of the largest Histiocytosis Programs in the world, our internationally-recognized research discoveries have led to a better understanding of histiocytic diseases.
Our Leukemia Program is the largest in the country and leads the nation in the development of an innovative approach to treat infants with leukemia that has improved the survival rate from 30% to 75%.
The Liver Tumor Program's principle areas of research span from basic science to clinical research, with particular emphasis on tumor biology and the identification of new targets for therapies.
Our principle areas of pediatric lymphoma research focus on understanding the genetic determinants of tumor biology, exploiting the relationship of lymphoma with the immune system to develop immunotherapy, and in new drug development.
Our translational program is nationally recognized for the development and use of immunotherapy in patients with relapsed or refractory disease.